Posted by Michael Wonder on 13 Feb 2023
Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
31 January 2023 - Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited discounts for its biosimilar version of Humira — the world’s best-selling medicine — and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patients.
Here’s why: the drug company will offer its medication, called Amjevita, at two different discounts — 5% and 55% — off the roughly $80,000 wholesale, or list, price.
